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Background/aim: The aim of this study was to determine the specific component of Rosmarinus officinalis (RO) responsible for
increased flap survival and how RO displays its efficacy.
Materials and methods: Rectangular random-pattern flaps were elevated from the back of each rat. Group I was the control group. In
group II 0.1 mL of cineole, in group III 0.1 mL of alpha-pinene, in group IV 0.1 mL of camphor, in group V 0.1 mL each of alpha-pinene
and cineole, in group VI 0.1 mL each of alpha-pinene and camphor, in group VII 0.1 mL each of cineole and camphor, and in group VIII,
0.1 mL each of alpha-pinene, cineole, and camphor was orally administered once a day before surgery. The luminal area of the largest
blood vessel in the proximal flap was measured. Interleukin-1, tumor necrosis factor alpha, thiobarbituric acid reactive substances, and
vascular endothelial growth factor values were measured.
Results: The mean percentage of the viable surface area was significantly greater in groups VIII, III, and V. The mean percentage of vessel
diameter was significantly greater in groups V, VIII, and VII.
Conclusion: We suggest that alpha-pinene and cineole were the components of RO that were responsible for increased flap survival. The
most effective of feature of RO was the antiinflammatory effects.
Key words: Rosmarinus officinalis, flap survivability, tissue defect, rosemary

1. Introduction
Random-patterned skin flaps are often created during
plastic surgery procedures; however, necrosis can occur
as a complication. Improving the survival of randompatterned skin flaps is an important goal to reduce duration
of hospitalization, additional surgical procedures, and
treatment costs. Although many agents have been used
for improving skin flap survival, none that can completely
prevent flap necrosis has been identified (1–4).
Rosmarinus officinalis (RO) is the one of the agents that
have been used systemically and topically in the prevention
of flap necrosis (5,6). RO has antimicrobial (7–10),
antioxidant (11–18), antiinflammatory (19,20), antifungal
(7,9,10), antidiabetic (15), anticarcinogenic (13,19),
antiplatelet (21), antimetastatic (13,19), antiproliferative
(16), and antimutagenic (22) effects.
In previous studies investigating the effects of RO on
the survival of skin flaps, the viable surface areas of ROtreated flaps were reported to be significantly greater in
all treated groups than that in control groups (5,6). The
* Correspondence: bilsevince@yahoo.com
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authors claimed that, in addition to antiinflammatory
and antioxidant effects, RO had vasodilatory effects that
contributed to increased flap survival. It was determined
that application of this oil increased skin flap survival;
however, they did not determine the specific component
responsible for the improvement. In addition, the specific
components that have a dominant effect in improving flap
survival are still unknown.
The aim of the present study was to determine the
specific component of RO responsible for increased flap
survival and how RO displays its efficacy. This study also
aimed to determine the components of RO that have
antiinflammatory, antioxidant, and vasodilatory effects.
2. Materials and methods
Female Wistar albino rats, aged 12–14 weeks and weighing
243–310 g, were divided into 8 groups comprising 7
rats each. The backs of all rats were shaved. Ketamine
hydrochloride (50 mg/kg) (Ketalar vial, Pfizer, USA)
and 5 mg/kg xylazine hydrochloride (Rompun amp,
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Bayer, Germany) were used for anesthesia and were
intraperitoneally administered before surgery. No dressing
was applied after surgery. The study was approved by
the ethics committee and conformed to the Helsinki
Declaration. The rats were followed under standard
laboratory conditions in the experimental medical
research and application center. The feed and water needs
of the animals were regularly met.
Group I was designated as the control group.
Rectangular random-patterned flaps measuring 8 × 2 cm
were elevated from the back of each rat. Electrocautery or
hemostatic agents were not used to control bleeding. The
flaps were primer sutured with monofilament absorbable
suture (Biosyn, Covidien, USA) to the location from where
they were elevated, and 0.1 mL of physiological serum was
orally administered with a repeater pipette (Eppendorf,
Hamburg, Germany) once daily for 1 week.
Cineole, alpha-pinene, and camphor solutions were
obtained with distillation from RO extract. The cineole
solution contained 73.6% cineole, 8.67% camphor, 5.07%
P-Cymene, 3.71% alpha pinene, 2.31% beta pinene,
1.93% camphene, 1.19% terpinolene, 1.5% dipropylene
glycol, 0.7% gamma terpinene, 0.55% delta 3 carene,
0.43% alpha terpineol, and 0.33% isoborneole. The alphapinene solution contained 62.19% alpha pinene, 15.85%
camphene, 8.17% cineole, 6.17% beta pinene, 4.38%
limonene, 1.19% P-Cymene, 0.59% camphor, 0.55% alpha
phellandrene, 0.42% delta 3 carene, 0.28% sabinene, and
0.22% myrcene. The camphor solution contained 85.8%
camphor, 6.14% dipropyleneglycol, 3.44% alpha terpineole,
3.19% isoborneol, and 0.92% cineole. The solutions were
diluted with physiological saline to 60% purity.
In group II, 0.1 mL of cineole (60% purity) (Aksu Vital,
Turkey) was orally administered once daily for 1 week
before surgery. At the end of the week, 0.1 mL of cineole
was orally re-administered 2 h prior to surgery. Skin
flaps were elevated and replaced as described for group I.
Cineole was orally administered once daily for 1 week.
In group III, 0.1 mL of alpha-pinene (60% purity) was
orally administered once daily for 1 week before surgery. At
the end of the week, 0.1 mL of alpha-pinene was orally readministered 2 h prior to surgery. Skin flaps were elevated
and replaced as described for group I. Alpha-pinene was
orally administered once daily for 1 week.
In group IV, 0.1 mL of camphor (60% purity) was
orally administered once daily for 1 week before surgery.
At the end of the week, 0.1 mL of camphor was orally readministered 2 h prior to surgery. Skin flaps were elevated
and replaced as described for group I. Camphor was orally
administered once daily for 1 week.
In group V, 0.1 mL each of alpha-pinene and cineole
was orally administered once daily for 1 week prior to
surgery. At the end of the week, 0.1 mL each of alpha-

pinene and cineole was orally re-administered 2 h prior to
surgery. Skin flaps were elevated and replaced as described
for group I. Alpha-pinene and cineole were orally
administered once daily for 1 week.
In group VI, 0.1 mL each of alpha-pinene and
camphor was orally administered once daily for 1 week
before surgery. At the end of the week, 0.1 mL each of
alpha-pinene and camphor was orally re-administered 2
h prior to surgery. Skin flaps were elevated and replaced
as described for group I. Alpha-pinene and camphor were
orally administered once daily for 1 week.
In group VII, 0.1 mL each of cineole and camphor
was orally administered once daily for 1 week before
surgery. At the end of the week, 0.1 mL each of cineole and
camphor was orally re-administered 2 h prior to surgery.
Skin flaps were elevated and replaced as described for
group I. Cineole and camphor were orally administered
once daily for 1 week.
In group VIII, 0.1 mL each of alpha-pinene, cineole,
and camphor was orally administered once a day for 1
week before surgery. At the end of the week, 0.1 mL each
of alpha-pinene, cineole, and camphor was orally readministered 2 h prior to surgery. Skin flaps were elevated
and replaced as described for group I. Alpha-pinene,
cineole, and camphor were orally administered once daily
for 1 week.
The flaps were evaluated 1 week after elevation. All
images were acquired using the same digital camera,
distance, position, and the viable and necrotic regions
were outlined on transparent paper. The surface area of
viable and necrotic regions was calculated. To eliminate
false-positive results caused by necrosis-induced
contraction, only the viable surface area was measured
(cm2) on transparent paper using a digital planimeter.
The surface area of the necrotic region was calculated by
subtracting the viable surface area from the total flap area
(16 cm2). A 2 × 2 cm excision biopsy specimen was taken
from the most proximal viable area of the flap. Specimens
were stained with hematoxylin and eosin and examined
under a light microscope. In each group, the luminal
area of the largest blood vessel and number of capillary
vessels in the papillary dermis of the proximal flap was
measured in 400× magnification area (1 high power
field). In addition, number of neovascularized vessels and
number of inflammatory cells (neutrophil, macrophage,
lymphocyte) in the reticular dermis of the proximal flap
were measured. The rats were sacrificed with taking 10
mL of blood intracardially. Interleukin-1 (IL-1), tumor
necrosis factor alpha (TNF-α), vascular endothelial growth
factor (VEGF), and thiobarbituric acid reactive substances
(TBARS) (Oxford Biomedical Research, Missouri,
USA) values were measured spectrophotometrically to
investigate antiinflammatory, antioxidant, and angiogenic
properties in the blood.
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The statistical significance of mean values was analyzed
using SPSS. One-way analysis of variance and Tukey’s post
hoc test were used to compare the viable surface area and
vessel diameter among the groups. P-values of <0.05 were
considered statistically significant.
3. Results
No rats died during the experiments. In addition, no
infection was observed.
3.1. Measurements for group I
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 28.63 ± 0.412%
(Figure 1). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 82.84 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5 ± 1 and the
mean number of neovascularized vessels was 14.75 ± 2.25.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 58.75 ± 11.25. The mean
value of IL-1 was 48.38, TNF-α 33.28, VEGF 12.16, and
TBARS 8.52 nmol/mL (Figure 2).
3.2. Measurements for group II
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 46.06 ± 1.298%
(Figure 3). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 64.02 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.2 ± 1.8 and the
mean number of neovascularized vessels was 13.8 ± 1.2.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 56 ± 16. The mean value
of IL-1 was 23.18, TNF-α 20.58, VEGF 15.65, and TBARS
6.57 nmol/mL (Figure 2).
3.3. Measurements for group III
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 62.56 ± 2.102%
(Figure 4). The mean value of the luminal area of the

Figure 1. The mean ratio of the viable surface area to the total
flap area was 28.63% ± 0.412% in group I a week after surgery.
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largest blood vessel in the proximal flap was 66.63 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.4 ± 1.6 and the
mean number of neovascularized vessels was 14.5 ± 1.5.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 48 ± 26. The mean value
of IL-1 was 18.88, TNF-α 19.46, VEGF 15.43, and TBARS
7.37 nmol/mL (Figure 2).
3.4. Measurements for group IV
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 38.63 ± 1.299%
(Figure 5). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 99.52 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.1 ± 1.1 and the
mean number of neovascularized vessels was 14.8 ± 2.2.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 44 ± 12. The mean value
of IL-1 was 17.51, TNF-α 28.31, VEGF 14.35, and TBARS
7.98 nmol/mL (Figure 2).
3.5. Measurements for group V
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 58.06 ± 1.027%
(Figure 6). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 146.95 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.3 ± 1.7 and the
mean number of neovascularized vessels was 14.9 ± 2.1.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 50 ± 15. The mean value
of IL-1 was 18.23, TNF-α 15.76, VEGF 25.15, and TBARS
6.72 nmol/mL (Figure 2).
3.6. Measurements for group VI
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 47.43 ± 1.027%
(Figure 7). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 97.05 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.1 ± 1.1 and the
mean number of neovascularized vessels was 13.6 ± 2.4.
The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 42 ± 18. The mean value of
IL-1 was 16.81, TNF-α 18.2, VEGF 15.41, and TBARS 7.16
nmol/mL (Figure 2).
3.7. Measurements for group VII
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 51.87 ± 1.027%
(Figure 8). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 113.44 ± 4
µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.4 ± 1.6 and the
mean number of neovascularized vessels was 14.81 ± 2.19.
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Table. The mean viable areas of the flaps and value of the luminal area of the largest blood vessel
in the proximal flap in all groups.
Group
no.

The mean viable areas
of the flaps (cm2)

The mean viable areas
of the flaps (%)

The mean value of the
luminal area (µm)

1

4.58

28.63

82.84

2

7.36

46.06

64.02

3

10

62.56

66.63

4

61.8

38.63

99.52

5

9.28

58.06

146.95

6

7.58

47.43

97.05

7

8.29

51.87

113.44

8

11.9

74.43

149.74

30
23

24

19

18
12

32.5
18

18

17

14

19.5

15.65

18.6833
15.4333

15.4167

6.5
GroupI

GroupII

GroupIII GroupIV GroupV

GroupVI GroupVII GroupVIII

0.0

GroupI

GroupII

GroupIII GroupIV GroupV GroupVI GroupVII GroupVIII

IL-1

VEGF
9.0

8.525

42.5
34.0

7.373
6.578

6.75

33.2833

7.985
6.725

7.16

7.51
6.64

28.3167

25.5

20.5833 19.4667
15.7667

17.0

18.2

4.5

21.6667
16.6333

2.25

8.5
0.0

23.4667

13.0 12.1667

9

6
0

25.15

26.0

18

0.0
GroupI

GroupII

GroupIII GroupIV GroupV

GroupVI GroupVII GroupVIII
GroupVIII

GroupI

TNF-alpha

GroupII

GroupIII GroupIV GroupV GroupVI GroupVII GroupVIII

TBARS

Figure 2. The mean value of IL-1, TNF-α, VEGF, and TBARS in all groups.

The mean number of inflammatory cells in the reticular
dermis of the proximal flap was 45 ± 15. The mean value of
IL-1 was 17.8, TNF-α 21.66, VEGF 18.68, and TBARS 7.51
nmol/mL (Figure 2).

3.8. Measurements for group VIII
One week after flap elevation, the mean ratio of the viable
surface area to the total flap area was 74.43 ± 1.027%
(Figure 9). The mean value of the luminal area of the
largest blood vessel in the proximal flap was 149.74 ± 4
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Figure 3. The mean ratio of the viable surface area to the total
flap area was 46.06 ± 1.298% in group II a week after surgery.

Figure 4. The mean ratio of the viable surface area to the total
flap area was 62.56 ± 2.102% in group III a week after surgery.

Figure 5. The mean ratio of the viable surface area to the total
flap area was 38.63 ± 1.299% in group IV a week after surgery.

Figure 6. The mean ratio of the viable surface area to the total
flap area was 58.06 ± 1.027% in group V a week after surgery.

Figure 7. The mean ratio of the viable surface area to the total
flap area was 47.43 ± 1.027% in group VI a week after surgery.

Figure 8. The mean ratio of the viable surface area to the total
flap area was 51.87 ± 1.027% in group VII a week after surgery.

µm (Table). The mean number of capillary vessels in the
papillary dermis of the proximal flap was 5.4 ± 1.6 and the
mean number of neovascularized vessels was 14.83 ± 2.17.
The mean number of inflammatory cells in the reticular

dermis of the proximal flap was 41 ± 19. The mean value of
IL-1 was 14.4, TNF-α 16.63, VEGF 23.46, and TBARS 6.64
nmol/mL (Figure 2).
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Figure 9. The mean ratio of the viable surface area to the total
flap area was 74.43 ± 1.027% in group VIII a week after surgery.

The mean percentage of the viable surface area was
significantly greater in all treatment groups than that
in group I, and was significantly greater in groups VIII,
III, and V than in groups II, IV, VI, and VII (P < 0.05).
The mean percentage of vessel diameter was significantly
greater (P < 0.05) in groups V, VIII, and VII than in group
I, and no statistically significant differences were found
between groups V and VIII (Figure 10). When the mean
number of capillary vessels in the papillary dermis of the
proximal flap was investigated, no statistically significant
differences were found between the groups. In all groups,
of the mean number of inflammatory cells in the reticular
dermis of the proximal flap, 5–6 were neutrophils, 5–6
were macrophages, and the rest were lymphocytes (Figure

11). No statistically significant differences were found
between the groups.
When the plasma level of VEGF was investigated, there
was no effect found in groups I, II, III, IV, and VI. Groups
V, VII, and VIII displayed effects. Moreover, no statistically
significant differences were found between groups V and
VIII.
When the plasma level of IL-1 was investigated, there
was no effect found in groups I and II. Groups III, IV, V,
VI, VII, and VIII had effects. The minimum level of IL-1
was in group VIII.
When the plasma level of TBARS was investigated,
there was no effect shown in groups I, IV, and VII. Groups
II, III, V, VI, and VIII had effects. However, no statistically
significant differences were found between groups II, III,
V, VI, and VIII.
When the plasma level of TNF-α was investigated,
there was no effect in group I. Groups II, III, IV, V, VI, VII,
and VIII had effects. Group IV displayed the least efficacy.
No statistically significant differences were found between
groups II, III, V, VI, VII, and VIII.
4. Discussion
Random-patterned skin flaps are widely used in soft tissue
reconstruction. If the procedure is not well-planned or
circulatory disorders occur, flap necrosis can become
a complication. Many studies have been performed to
improve the survival of random-patterned skin flaps. As
a result of anaerobic metabolism occurring in cells due
to ischemia occurring in the flap, free radicals increase
within the cell. This increase in free oxygen radicals and

Figure 10. Appearance of the luminal area of the largest blood vessel in the proximal flaps in group I (A), 2 (B), 3 (C), 4 (D), 5 (E), 6
(F), 7 (G), and 8 (H).
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Figure 11. Appearance of the inflammatory cells (neutrophil, macrophage, lymphocyte) in the reticular dermis of the proximal flaps in
group I (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 (G), and 8 (H).

neutrophils can lead to tissue damage, and subsequently
flap necrosis. Antiinflammatory drugs and antioxidants
have been used to reduce the cellular effects of ischemia
(23,24). In addition, RO can greatly enhance flap viability
with vasodilatory effects (5).
Increased blood circulation in the flap can prevent
necrosis. In a previous study, the authors claimed that RO
treatment is useful in patients with circulatory problems
and can be used as an alternative therapy to increase blood
circulation in flaps (5).
When these studies are considered together, the
bioavailability of RO is the highest when administered
orally (5,6). Thus, oral administration was used in our
study.
The proportions of the basic components of RO
vary among genotypes. These components and their
proportions are as follows: alpha-pinene (7.3%–37.8%),
camphene (0%–12.1%), myrcene (0%–6.6%), cymol (0%–
4.5%), limonene (0%–7.2%), 1.8-cineole (13.6%–67.3%),
camphor (2.2%–48.3%), and borneol (1.3%–12.7%) (25). In
a previous study, the authors used Kozan-genotype RO (5).
This genotype contains alpha-pinene (13.5%), camphene
(4.1%), myrcene (2.2%), cymol (2.8%), limonene (2.4%),
camphor (2.2%), borneol (5.3%), and 1.8-cineole (67.3%)
(25). In our study, most of the 3 components studied,
which were from the Kozan genotype, were obtained with
60% purity when the RO components were separated.
Cineole was evaluated by being administered singly in
group II. Cineole has antiinflammatory and antioxidant
properties. Alpha-pinene was evaluated by being
administered singly in group III. Alpha-pinene also has
antiinflammatory and antioxidant properties. Camphor
has only antiinflammatory properties.
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There were no statistically significant differences found
in VEGF compared to the groups in which components of
RO were given singly. However, VEGF was significantly
higher in groups V, VII, and VIII, in which RO components
were given in combination. We hypothesized that although
no RO components had an angiogenesis feature, the
components may be mutually induced. Three components
of RO were given in group VIII. The antiinflammatory
effect was highest in this group; in addition, group VIII had
antioxidant properties and the VEGF plasma level was high.
There were antiinflammatory and antioxidant
properties and the VEGF plasma level was high in group
V, in which alpha-pinene and cineole were given together.
We performed flap elevation after 1 week of treatment
because the average ratio of the viable surface area to the
total flap area was found to be the highest in previous
studies investigating the effects of RO on flap viability (5,6).
Flap elevation after 1 week of treatment can increase flap
survival in clinical practice. In addition, it was suggested
that the bioavailability of RO is the greatest when orally
administered (5,6). Thus, oral administration was used in
our study.
Although the average ratio of the viable surface area in
the control groups was similar in previous studies and in
our study, it was different in the experimental groups. The
average ratio of viable surface area was 67.68% and 96% in
previous studies (5,6). However, in our study, the highest
average ratio of viable surface area was 74% in group VIII,
in which all 3 components were given. The reason for this
difference could be that we used only 3 components of RO
in the experimental groups. Other components of RO such
as camphene, myrcene, cymol, limonene, and borneol may
also increase flap survival. On the other hand, in group
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VIII, unlike the Kozan genotype of RO, more alphapinene and camphor were given to the rats. Although
alpha-pinene and camphor have antiinflammatory and
antioxidant properties, the flap viability was poorer than
that in a previous study. Giving a substance that has higher
purity or a more concentrated amount does not mean
that it will be more effective. Another probability may be
that other components of RO induce the effects of alphapinene, cineole, and camphor.
The amount of cineole, which is 67.3% in the Kozan
genotype (5), had 60% purity in our study. This difference
created a significant difference in flap viability. Cineole and
alpha-pinene both displayed antioxidant properties, and
the flap viable area rate was the third highest in group V, in
which these two components were administered together.
However, the second highest viable area was in group III,
in which alpha-pinene was given singly.

When flap viable areas were compared, the most viable
areas were in groups VIII, III, V, and VII. The common
feature of these groups was the antiinflammatory effect.
The common component of RO in groups VIII, III, and
V was alpha-pinene. In addition, the common component
of RO in groups VIII, V, and VII was cineole. We suggest
that alpha-pinene and cineole were the components of
RO that were responsible for increased flap survival.
As a result, although RO was effective in flap viability
with antiinflammatory, antioxidant, and vasodilatory
properties and in increasing VEGF, the most effective of
these features were the antiinflammatory effects.
This study demonstrated that cineole, alpha-pinene,
and camphor can help to prevent flap necrosis; however,
investigation of other components of RO for their effects
on the viability of flaps is also required in further studies.
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